$160 Million is the total value of Opaleye Management Inc.'s 52 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 58.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXGN | AXOGEN INC | $11,363,000 | +7.2% | 2,120,000 | 0.0% | 7.09% | +59.9% | |
| ARIA | Sell | ARIAD PHARMACEUTICALS INC | $7,988,000 | -2.4% | 1,250,000 | -4.6% | 4.98% | +45.5% |
| RARE | ULTRAGENYX PHARMACEUTICAL IN | $6,964,000 | -43.6% | 110,000 | 0.0% | 4.34% | -15.8% | |
| FGEN | FIBROGEN INC | $6,919,000 | -30.1% | 325,000 | 0.0% | 4.32% | +4.2% | |
| Buy | PROTALIX BIOTHERAPEUTICS INC | $6,892,000 | -16.6% | 8,200,000 | +1.2% | 4.30% | +24.4% | |
| MDGN | Buy | MEDGENICS INC | $6,854,000 | -18.1% | 1,557,700 | +12.1% | 4.27% | +22.1% |
| ADMS | Buy | ADAMAS PHARMACEUTICALS INC | $6,064,000 | +12.7% | 320,000 | +68.4% | 3.78% | +68.1% |
| CARA | Buy | CARA THERAPEUTICS INC | $5,318,000 | -26.1% | 855,000 | +100.2% | 3.32% | +10.2% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $5,290,000 | -9.3% | 165,000 | +65.0% | 3.30% | +35.3% |
| AMAG | Buy | AMAG PHARMACEUTICALS INC | $5,148,000 | +13.7% | 220,000 | +46.7% | 3.21% | +69.5% |
| IMMY | Buy | IMPRIMIS PHARMACEUTICALS INC | $4,963,000 | -40.6% | 1,250,000 | +3.7% | 3.10% | -11.4% |
| INOTEK PHARMACEUTICALS CORP | $4,773,000 | -34.7% | 645,000 | 0.0% | 2.98% | -2.6% | ||
| DEPO | Buy | DEPOMED INC | $4,527,000 | -16.8% | 325,000 | +8.3% | 2.82% | +24.1% |
| AGIO | New | AGIOS PHARMACEUTICALS INC | $4,263,000 | – | 105,000 | +100.0% | 2.66% | – |
| CYTRX CORP | $4,118,000 | +7.9% | 1,440,000 | 0.0% | 2.57% | +61.0% | ||
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $3,971,000 | -45.2% | 220,000 | -20.0% | 2.48% | -18.3% |
| GERN | Sell | GERON CORP | $3,869,000 | -56.2% | 1,325,000 | -27.4% | 2.41% | -34.7% |
| FOMX | Buy | FOAMIX PHARMACEUTICALS LTD | $3,847,000 | -5.1% | 590,000 | +18.0% | 2.40% | +41.5% |
| CDXS | Sell | CODEXIS INC | $3,665,000 | -45.8% | 1,178,500 | -26.3% | 2.28% | -19.3% |
| TGTX | Buy | TG THERAPEUTICS INC | $3,536,000 | -1.2% | 415,000 | +38.3% | 2.20% | +47.4% |
| CMRX | New | CHIMERIX INC | $3,449,000 | – | 675,000 | +100.0% | 2.15% | – |
| OPHT | Sell | OPHTHOTECH CORP | $3,382,000 | -59.0% | 80,000 | -23.8% | 2.11% | -38.8% |
| IMMU | Buy | IMMUNOMEDICS INC | $3,313,000 | +272.2% | 1,325,000 | +356.9% | 2.07% | +455.4% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $2,796,000 | +15.9% | 400,000 | +33.3% | 1.74% | +73.0% |
| AMRN | AMARIN CORP PLC | $2,693,000 | -19.0% | 1,760,000 | 0.0% | 1.68% | +20.7% | |
| Buy | INTEC PHARMA LTD JERUSALEM | $2,629,000 | -22.1% | 638,000 | +1.3% | 1.64% | +16.1% | |
| NBRV | Buy | NABRIVA THERAPEUTICS AGsponsored adr | $2,453,000 | +15.9% | 273,800 | +24.5% | 1.53% | +72.9% |
| EGRX | Sell | EAGLE PHARMACEUTICALS INC | $2,430,000 | -67.8% | 60,000 | -29.4% | 1.52% | -51.9% |
| AFMD | Buy | AFFIMED N V | $2,281,000 | -46.2% | 610,000 | +2.5% | 1.42% | -19.7% |
| ZGNX | New | ZOGENIX INC | $2,218,000 | – | 240,000 | +100.0% | 1.38% | – |
| RTRX | Sell | RETROPHIN INC | $2,049,000 | -69.2% | 150,000 | -56.5% | 1.28% | -54.1% |
| SUPN | Sell | SUPERNUS PHARMACEUTICALS INC | $1,906,000 | -66.2% | 125,000 | -70.2% | 1.19% | -49.6% |
| Sell | TRILLIUM THERAPEUTICS INC | $1,804,000 | -31.9% | 195,000 | -7.1% | 1.12% | +1.6% | |
| EDGE | New | EDGE THERAPEUTICS INC | $1,693,000 | – | 185,000 | +100.0% | 1.06% | – |
| CYNA | Buy | CYNAPSUS THERAPEUTICS INC | $1,440,000 | -14.4% | 121,000 | +10.0% | 0.90% | +27.7% |
| ADAP | New | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $1,425,000 | – | 175,300 | +100.0% | 0.89% | – |
| CORI | Buy | CORIUM INTL INC | $1,390,000 | -51.8% | 360,000 | +1.4% | 0.87% | -28.0% |
| EARS | Sell | AURIS MED HLDG AG | $1,238,000 | -32.5% | 340,000 | -9.3% | 0.77% | +0.7% |
| OHRP | New | OHR PHARMACEUTICAL INC | $1,175,000 | – | 366,000 | +100.0% | 0.73% | – |
| New | PROTEON THERAPEUTICS INC | $1,161,000 | – | 150,000 | +100.0% | 0.72% | – | |
| XOMA | Sell | XOMA CORP DEL | $1,044,000 | -53.8% | 1,350,000 | -20.6% | 0.65% | -31.1% |
| TENX | Sell | TENAX THERAPEUTICS INC | $1,024,000 | -42.2% | 499,600 | -7.5% | 0.64% | -13.6% |
| AKAOQ | New | ACHAOGEN INC | $704,000 | – | 255,000 | +100.0% | 0.44% | – |
| NKTR | New | NEKTAR THERAPEUTICS | $688,000 | – | 50,000 | +100.0% | 0.43% | – |
| MDVN | New | MEDIVATION INC | $667,000 | – | 14,500 | +100.0% | 0.42% | – |
| EVOK | EVOKE PHARMA | $662,000 | +54.3% | 130,000 | 0.0% | 0.41% | +130.7% | |
| PRTA | New | PROTHENA CORP PLC | $576,000 | – | 14,000 | +100.0% | 0.36% | – |
| New | NEURODERM LTD | $544,000 | – | 38,500 | +100.0% | 0.34% | – | |
| NVLS | New | NIVALIS THERAPEUTICS INC | $417,000 | – | 100,000 | +100.0% | 0.26% | – |
| ACRS | New | ACLARIS THERAPEUTICS INC | $341,000 | – | 18,000 | +100.0% | 0.21% | – |
| BLRX | BIOLINERX LTDsponsored adr | $255,000 | -21.5% | 250,000 | 0.0% | 0.16% | +16.9% | |
| CHMA | New | CHIASMA INC | $183,000 | – | 20,000 | +100.0% | 0.11% | – |
| SGMO | Exit | SANGAMO BIOSCIENCES INC | $0 | – | -60,000 | -100.0% | -0.23% | – |
| Exit | ACHAOGEN INC | $0 | – | -125,000 | -100.0% | -0.30% | – | |
| VTAE | Exit | VITAE PHARMACEUTICALS INC | $0 | – | -58,500 | -100.0% | -0.44% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -35,000 | -100.0% | -0.45% | – |
| CLLS | Exit | CELLECTIS S Asponsored ads | $0 | – | -50,000 | -100.0% | -0.65% | – |
| AXDX | Exit | ACCELERATED DIAGNOSTICS INC | $0 | – | -75,000 | -100.0% | -0.67% | – |
| ALDR | Exit | ALDER BIOPHARMACEUTICALS INC | $0 | – | -65,000 | -100.0% | -0.90% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -150,000 | -100.0% | -0.92% | – |
| AGRX | Exit | AGILE THERAPEUTICS INC | $0 | – | -300,000 | -100.0% | -1.22% | – |
| FLML | Exit | FLAMEL TECHNOLOGIES SAsponsored adr | $0 | – | -250,000 | -100.0% | -1.28% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -55,000 | -100.0% | -1.30% | – |
| Exit | LA JOLLA PHARMACEUTICAL CO | $0 | – | -140,000 | -100.0% | -1.58% | – | |
| AVGR | Exit | AVINGER INC | $0 | – | -190,000 | -100.0% | -1.80% | – |
| TNXP | Exit | TONIX PHARMACEUTICALS HLDG C | $0 | – | -565,000 | -100.0% | -1.81% | – |
| CEMP | Exit | CEMPRA INC | $0 | – | -200,000 | -100.0% | -2.60% | – |
| RLYP | Exit | RELYPSA INC | $0 | – | -220,000 | -100.0% | -2.61% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-05-27
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.